Jump to content

Antithyroid agent

From Wikipedia, the free encyclopedia
(Redirected from Antithyroid agents)

An antithyroid agent is a hormone inhibitor acting upon thyroid hormones.

The main antithyroid drugs are carbimazole (in the UK), methimazole (in the US), and propylthiouracil (PTU). A less common antithyroid agent is potassium perchlorate.

Classification based on mechanisms of action

[edit]

The mechanisms of action of antithyroid drugs are not completely understood. Based on their mechanisms of action, the drugs are classified into following six classes.

Thyroid hormone synthesis inhbitors

[edit]

These drugs probably inhibit the enzyme thyroid peroxidase (a.k.a. thyroperoxidase), decreasing iodide oxidation, iodination of tyrosyl residues in thyroglobulin, and coupling of iodotyrosyl and iodothyronyl residues.[1] It is thought that they inhibit the thyroperoxidase-catalyzed oxidation reactions by acting as substrates for the postulated peroxidase-iodine complex, thus competitively inhibiting the interaction with the amino acid tyrosine. The most common drugs in this class are thioamides, which include propylthiouracil, methimazole and its prodrug carbimazole.

Additionally, propylthiouracil may reduce the de-iodination of thyroxine (T4) into triiodothyronine (T3) in peripheral tissues.[2]

Lugol's iodine is used to temporarily block thyroid hormone synthesis before surgeries.[3] It is also used to treat patients with thyroid storm or, more commonly, to reduce thyroid vascularity before thyroidectomy (surgical removal of the thyroid gland).[4]

Iodide uptake inhibitors

[edit]

They decrease uptake of iodide ions (I−) into follicular cells of the thyroid gland. Since their molecules have structural similarities with the iodide ion, they compete with iodide for being transported by the sodium/iodide symporter, which is a transporter protein that co-transports Na+ and I− ions. Iodide transport is a key step in the biosynthesis of the thyroid hormones T4 and T3.[5][6] For example, potassium perchlorate competitively inhibits the active iodide transport mechanism in the thyroid gland, which has the capacity to selectively concentrate iodide against a large concentration gradient.[5][6]

Besides perchlorates, other examples of iodide uptake inhibitors include pertechnetates, thiocyanates, nitrates.[7]

These drugs are no longer used due to high toxicity and adverse effects.[8][9]

Thyroid hormone release inhibitors

[edit]

They inhibit release (secretion) of thyroid hormones by the thyroid gland. The most studied drug in this class is lithium, which inhibits thyroid hormone secretion by inhibiting iodotyrosine coupling, thyroidal iodide uptake, and alteration in structure of thyroglobulin,[10] a protein which acts as a substrate for the synthesis of thyroid hormones and storage of inactive forms of T3, T4 and iodine within the lumen of thyroid follicular cells.[11] Since lithium is neither metabolized nor protein-bound, its bioavailability usually is close to 100%.[12] Hence, there are risks of serious side effects such as lithium toxicity, hypothyroidism, and diabetes insipidus.[13]

Excess iodine

[edit]

Excessive iodine intake can temporarily inhibit production of thyroid hormones. This occurs because of the Wolff-Chaikoff effect, which is a phenomenon of rejection of large quantities of iodine by the thyroid gland, therefore preventing it from synthesizing large quantities of thyroid hormones.[14]

Iodine radiopharmaceuticals

[edit]
Main articles: Isotopes of iodine and radiopharmaceutical

They are radioisotopes of iodine. In small doses, when they are taken up by overactive thyroid follicular cells, they emit small amounts of beta radiation that destroys not all, but many thyroid follicular cells, thereby reducing thyroid hormone production.[15] This is a form of targeted therapy for hyperthyroidism. Since even low levels of ionizing radiation are highly mutagenic and can cause cancer,[16] less toxic iodine isotopes such as iodine-123[17] are more commonly used in nuclear imaging, while iodine-131 is used for its cytolytic (cell-destroying) effects in hyperthyroidism and thyroid tumors.[15]

Thyroid hormone receptor antagonists

[edit]

Also called TR antagonists, they inhibit action of thyroid hormones by blocking TR receptors (thyroid hormone receptors). Antagonist 1-850 and its derivatives have been found to be coactivator interaction inhibitors, which interfere with the interaction between TR receptors and coactivator proteins such as nuclear hormone receptor coregulator (NRC). As a result, the receptors are unable to recruit coactivators, causing stoppage of transcription of target genes, thereby preventing activation of TR receptors, ultimately leading to inhibition of effects of thyroid hormones because they can bind to only inactive TR receptors, and these receptors can't be activated in presence of TR antagonists.[18] Antagonist 1-850 has also been found to inhibit binding of [125I]T3[a] to TRs in intact GH4 cells.[18]

Adverse effects

[edit]

The most dangerous side effect is agranulocytosis (1/250, more in PTU); this is an idiosyncratic reaction which generally resolves on cessation of drug. It occurs in about 0.2 to 0.3% of cases treated with antithyroid drugs.[19] Other side effects include granulocytopenia (dose dependent, which improves on cessation of the drug) and aplastic anemia, and in case of propylthiouracil, severe, fulminant liver failure.[20] Patients on these medications should see a doctor if they develop sore throat or fever.

The most common side effects are rash and peripheral neuritis.[21] These drugs also cross the placenta and are secreted in breast milk.[22]

Graves' disease

[edit]

In Graves' disease, treatment with antithyroid medications must be given for six months to two years, in order to be effective. Even then, upon cessation of the drugs, the hyperthyroid state may recur. Side effects of the antithyroid medications include a potentially fatal reduction in the level of white blood cells.

A randomized control trial testing single dose treatment for Graves' found methimazole achieved euthyroidism (normal thyroid function that occurs within normal serum levels of TSH and T4[23]) more effectively after 12 weeks than did propylthiouracil (77.1% on methimazole 15 mg vs 19.4% in the propylthiouracil 150 mg groups).[24] But generally both drugs are considered equivalent.

A study has shown no difference in outcome for adding thyroxine to antithyroid medication and continuing thyroxine versus placebo after antithyroid medication withdrawal. However, two markers were found that can help predict the risk of recurrence. These two markers are an elevated level of thyroid stimulating hormone receptor antibodies (TSHR-Ab) and smoking. A positive TSHR-Ab at the end of antithyroid drug treatment increases the risk of recurrence to 90% (sensitivity 39%, specificity 98%), a negative TSHR-Ab at the end of antithyroid drug treatment is associated with a 78% chance of remaining in remission. Smoking was shown to have an impact independent to a positive TSHR-Ab.[25]

Competitive antagonists of thyroid stimulating hormone receptors are currently being investigated as a possible treatment for Grave's disease.

See also

[edit]

Notes

[edit]
  1. ^ [125I]T3 is a radiopharmaceutical formulation of triiodothyronine having iodine-125 atoms instead of iodine.

References

[edit]
  1. ^ "Thioamide - an overview | ScienceDirect Topics". www.sciencedirect.com. Archived from the original on 2023-09-27. Retrieved 2023-10-03.
  2. ^ Manna D, Roy G, Mugesh G (2013). "Antithyroid Drugs and their Analogues: Synthesis, Structure and Mechanism of Action". Acc. Chem. Res. 46 (11): 2706–15. doi:10.1021/ar4001229. PMID 23883148.
  3. ^ Erbil, Yeşim; Ozluk, Yasemin; Giriş, Murat; Salmaslıoglu, Artur; Issever, Halim; Barbaros, Umut; Kapran, Yersu; Özarmağan, Selçuk; Tezelman, Serdar (2007). "Effect of Lugol Solution on Thyroid Gland Blood Flow and Microvessel Density in the Patients with Graves' Disease". The Journal of Clinical Endocrinology & Metabolism. 92 (6): 2182–2189. doi:10.1210/jc.2007-0229. PMID 17389702.
  4. ^ Pearce, Elizabeth N. (2006-06-08). "Diagnosis and management of thyrotoxicosis". BMJ. 332 (7554): 1369–1373. doi:10.1136/bmj.332.7554.1369. ISSN 0959-8138. PMC 1476727. PMID 16763249.
  5. ^ a b Furman, B. L. "Potassium Perchlorate - an overview | ScienceDirect Topics". www.sciencedirect.com. Archived from the original on 2023-10-03. Retrieved 2023-10-03.
  6. ^ a b Wolff, J. (March 1998). "Perchlorate and the thyroid gland". Pharmacological Reviews. 50 (1): 89–105. ISSN 0031-6997. PMID 9549759.
  7. ^ Mervish, Nancy A.; Pajak, Ashley; Teitelbaum, Susan L.; Pinney, Susan M.; Windham, Gayle C.; Kushi, Lawrence H.; Biro, Frank M.; Valentin-Blasini, Liza; Blount, Benjamin C.; Wolff, Mary S.; for the Breast Cancer and Environment Research Project (BCERP) (April 2016). "Thyroid Antagonists (Perchlorate, Thiocyanate, and Nitrate) and Childhood Growth in a Longitudinal Study of U.S. Girls". Environmental Health Perspectives. 124 (4): 542–549. doi:10.1289/ehp.1409309. ISSN 0091-6765. PMC 4829993. PMID 26151950.
  8. ^ Wyngaarden, J. B.; Stanbury, J. B.; Rapp, B. (May 1953). "The effects of iodine, perchlorate, thiocyanate, and nitrate administration upon the iodide concentrating mechanism of the rat thyroid". Endocrinology. 52 (5): 568–574. doi:10.1210/endo-52-5-568. ISSN 0013-7227. PMID 13060263.
  9. ^ Serrano-Nascimento, Caroline; Nunes, Maria Tereza (2022). "Perchlorate, nitrate, and thiocyanate: Environmental relevant NIS-inhibitors pollutants and their impact on thyroid function and human health". Frontiers in Endocrinology. 13. doi:10.3389/fendo.2022.995503. ISSN 1664-2392. PMC 9633673. PMID 36339434.
  10. ^ Lazarus, J.h. (October 1998). "The Effects of Lithium Therapy on Thyroid and Thyrotropin-Releasing Hormone". Thyroid. 8 (10): 909–913. doi:10.1089/thy.1998.8.909. ISSN 1050-7256. PMID 9827658.
  11. ^ "TG thyroglobulin [Homo sapiens (human)] – Gene – NCBI". National Center for Biotechnology Information (NCBI). Retrieved 2019-09-16.
  12. ^ Ware, Kenric; Tillery, Erika; Linder, Lauren (January 2016). "General pharmacokinetic/pharmacodynamic concepts of mood stabilizers in the treatment of bipolar disorder". The Mental Health Clinician. 6 (1): 54–61. doi:10.9740/mhc.2016.01.054. ISSN 2168-9709. PMC 6009247. PMID 29955448.
  13. ^ "Lithium Salts". The American Society of Health-System Pharmacists. Archived from the original on 8 December 2015. Retrieved 1 December 2015.
  14. ^ Markou, K.; Georgopoulos, N.; Kyriazopoulou, V.; Vagenakis, A.g. (May 2001). "Iodine-Induced Hypothyroidism". Thyroid. 11 (5): 501–510. doi:10.1089/105072501300176462. ISSN 1050-7256. PMID 11396709.
  15. ^ a b "Iodide I-131". go.drugbank.com. Retrieved 2023-10-03.
  16. ^ Zelensky, Alex N.; Schoonakker, Mascha; Brandsma, Inger; Tijsterman, Marcel; Gent, Dik C. van; Essers, Jeroen; Kanaar, Roland (2020-01-16). "Low dose ionizing radiation strongly stimulates insertional mutagenesis in a γH2AX dependent manner". PLOS Genetics. 16 (1): e1008550. doi:10.1371/journal.pgen.1008550. ISSN 1553-7404. PMC 6964834. PMID 31945059.
  17. ^ Kim, Phillip D.; Tran, Huyen D. (2023), "I-123 Uptake", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32644740, retrieved 2023-10-03
  18. ^ a b Schapira, Matthieu; Raaka, Bruce M.; Das, Sharmistha; Fan, Li; Totrov, Maxim; Zhou, Zhiguo; Wilson, Stephen R.; Abagyan, Ruben; Samuels, Herbert H. (2003-06-10). "Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking". Proceedings of the National Academy of Sciences. 100 (12): 7354–7359. Bibcode:2003PNAS..100.7354S. doi:10.1073/pnas.1131854100. ISSN 0027-8424. PMC 165879. PMID 12777627.
  19. ^ Zambrana, J.; Zambrana, F.; Neto, F.; Gonçalves, A.; Zambrana, F.; Ushirohira, J. (2005). "Agranulocytosis with tonsillitis associated with methimazole therapy". Brazilian Journal of Otorhinolaryngology. 71 (3): 374–377. doi:10.1016/S1808-8694(15)31339-2. PMC 9450596. PMID 16446945.
  20. ^ Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, et al. (July 2009). "The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration". Thyroid. 19 (7): 673–4. doi:10.1089/thy.2009.0169. PMID 19583480.
  21. ^ Pal, Partha; Ray, Sayantan; Biswas, Kaushik; Maiti, Animesh; Mukhopadhyay, Deep; George, Rintu; Mukherjee, Debabrata (September 2014). "Thyrotoxic neuropathy; an under recognized condition: A clinical vignette". Thyroid Research and Practice. 11 (3): 118. doi:10.4103/0973-0354.138559. ISSN 0973-0354.
  22. ^ Kampmann, Jens P.; Hansen, J. Mølholm (1981-12-01). "Clinical Pharmacokinetics of Antithyroid Drugs". Clinical Pharmacokinetics. 6 (6): 401–428. doi:10.2165/00003088-198106060-00001. ISSN 1179-1926. PMID 6172233. S2CID 33852149.
  23. ^ "Euthyroidism - an overview | ScienceDirect Topics". www.sciencedirect.com. Archived from the original on 2023-10-03. Retrieved 2023-10-03.
  24. ^ Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdit T, Nitiyanant W, Vichayanrat A (2001). "Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism". Clinical Endocrinology (Oxford). 54 (3): 385–90. doi:10.1046/j.1365-2265.2001.01239.x. PMID 11298092. S2CID 24463399.
  25. ^ Glinoer D, de Nayer P, Bex M (2001). "Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study". Eur. J. Endocrinol. 144 (5): 475–83. doi:10.1530/eje.0.1440475. PMID 11331213.
[edit]
Retrieved from "https://wiki.riteme.site/w/index.php?title=Antithyroid_agent&oldid=1239176648"